Literature DB >> 2883406

High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease.

C M Roifman, H Levison, E W Gelfand.   

Abstract

In a randomised cross-over study 12 patients with antibody deficiency and chronic lung disease received monthly infusions of either 0.6 g/kg or 0.2 g/kg intravenous immunoglobulin for six months, and were then switched to the alternative dose for a further six months. Although the incidence of infections did not differ greatly in the high-dose and low-dose phases, the frequency of acute infection was substantially reduced in those periods when serum IgG was 500 mg/dl or more. Pulmonary function worsened on the low-dose regimen and improved on the high-dose regimen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883406     DOI: 10.1016/s0140-6736(87)90494-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  58 in total

1.  Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.

Authors:  Michael Borte; Isabella Quinti; Annarosa Soresina; Eduardo Fernández-Cruz; Bruce Ritchie; Dirk S Schmidt; Christine McCusker
Journal:  J Clin Immunol       Date:  2011-09-20       Impact factor: 8.317

Review 2.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Self-infusion with immunoglobulin at home.

Authors:  H Chapel; V Brennan
Journal:  J Clin Pathol       Date:  1991-05       Impact factor: 3.411

4.  Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.

Authors:  J N Moy; A M Scharenberg; M R Stein; D Suez; R L Roberts; R J Levy; M Ballow; M B Fasano; C H Dash; S J Leach
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

Review 5.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

Review 6.  Clinical immunology in practice, new opportunities.

Authors:  Mark R Stein
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

7.  Echocardiographic abnormalities in primary antibody deficiency.

Authors:  S L Johnston; S J Hill; R J Lock; J F Dwight; D J Unsworth; M M Gompels
Journal:  Postgrad Med J       Date:  2004-04       Impact factor: 2.401

Review 8.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.

Authors:  Melvin Berger; Charlotte Cunningham-Rundles; Francisco A Bonilla; Isaac Melamed; Johann Bichler; Othmar Zenker; Mark Ballow
Journal:  J Clin Immunol       Date:  2007-05-04       Impact factor: 8.317

10.  Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.

Authors:  Mark R Stein; Robert P Nelson; Joseph A Church; Richard L Wasserman; Michael Borte; Christiane Vermylen; Johann Bichler
Journal:  J Clin Immunol       Date:  2008-09-24       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.